A multi-center randomized phase II study of nivolumab in combination with gemcitabine/cisplatin or ipilimumab as first line therapy for patients with advanced unresectable biliary tract cancer.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. TPS4142-TPS4142 ◽  
Author(s):  
Vaibhav Sahai ◽  
Kent A. Griffith ◽  
Muhammad Shaalan Beg ◽  
Mark Zalupski
Keyword(s):  
Biliary Tract ◽  
Phase Ii ◽  
Biliary Tract Cancer ◽  
Phase Ii Study ◽  
First Line ◽  
Tract Cancer ◽  
First Line Therapy ◽  
Line Therapy ◽  
Randomized Phase Ii

scholarly journals Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp)

ESMO Open ◽  
2022 ◽  
Vol 7 (1) ◽  
pp. 100314
Author(s):  
M.M. Javle ◽  
D.-Y. Oh ◽  
M. Ikeda ◽  
W.-P. Yong ◽  
K. Hsu ◽  
...  
Keyword(s):  
Biliary Tract ◽  
Phase Ii ◽  
Biliary Tract Cancer ◽  
Phase Ii Study ◽  
Second Line ◽  
Tract Cancer ◽  
Randomized Phase Ii
Sign in / Sign up

Export Citation Format

Share Document